Cannabinoids Events Pharmaceutical THC 
NORML
MAY 26, 2020
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo.
Cannabis Law Report
JANUARY 3, 2022
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Importantly, the FDA noted that a challenge model whereby subjects are exposed to THC in a controlled clinical setting may be acceptable to investigate primary efficacy, which would allow for the more efficient development of ANEB-001.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 12, 2021
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. 11,141,404, titled “Formulations And Methods For Treating Acute Cannabinoid Overdose.” ” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose.
Project CBD
MAY 3, 2023
Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. It’s kind of a bridge between THC and CBD.
Cannabis Law Report
SEPTEMBER 22, 2021
Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. The agreement may be terminated for a material breach, insolvency or, on a category-by-category basis, in the event that OCT has ceased development of a category of compounds (e.g.,
Cannabis Law Report
JANUARY 4, 2022
AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Our lead product, ANEB-001, has the potential to rapidly reverse the effects of acute cannabinoid intoxication, a relatively unknown yet serious affliction that sends more than 5,000 Americans to the hospital emergency department every day.
Cannabis Info
OCTOBER 4, 2019
The Scientist Who Identified THC Is Now Working on Synthetic Cannabinoids. Dr. Raphael Mechoulam , the scientist who first recognized the THC molecule in 1965, introduced his latest mission in California final week: constructing artificial cannabinoids. The plant produces a group of compounds called cannabinoid acids.
Expert insights. Personalized for you.
247 
Let's personalize your content